All In Biotech

Drug Trial Radar · NCT07124221

A Phase III Clinical Study of Cabergoline Tablets Compared With Bromocriptine Mesylate Tablets

A Randomized, Double-blind, Double-dummy, Positive Controlled, Multicenter Clinical Study to Evaluate the Efficacy and Safety of Cabergoline Tablets Compared With Bromocriptine Mesylate Tablets in Female Patients With Hyperprolactinemia

Last checked: Nov 20, 2026Latest source record: Oct 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 382 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

382

Planned (sponsor's estimate)

Start

Sep 12, 2025

Primary completion

Nov 21, 2026

Study completion Dec 30, 2026

Sponsor

Sponsor type
Industry
First posted
Aug 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase III clinical study evaluating the efficacy and safety of cabergoline tablets versus bromocriptine mesylate tablets in patients with hyperprolactinemia

Conditions

  • Hyperprolactinemia

Interventions

  • Cabergoline tabletsDrug

    Cabergoline tablets will be administered for 14 weeks.The allowed dose range is from 0.25 mg (1 tablet) QW to 1mg (4 tablets) QW. Dosage adjustments are made based on the serum PRL level.

  • Bromocriptine mesylate tabletsDrug

    Bromocriptine mesylate tablets was administered for 14 weeks.The dose is 1.25 mg (0.5 tablet) QD to 7.5mg 3 tablets) QD. Dosage adjustments are made based on the serum PRL level.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The percentage of subjects whose serum PRL levels returned to normalTime frame: 14 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking Union Hospital, Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.